← Back to Search

CAR T-cell Therapy

FSHR-Targeted T Cell Therapy for Ovarian Cancer

Phase 1
Recruiting
Led By Robert M Wenham, MD, MS, FACOG, FACS
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have had 1 prior platinum-based chemotherapeutic regimen for the management of ovarian, primary peritoneal, or fallopian tube carcinoma and at least 2 prior chemotherapy regimens.
No prior immunotherapy with checkpoint blockade in the 6 months before the T-cell infusion.
Must not have
Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess.
Abdominal surgery (for reasons other than IP port placement).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved

Summary

This trial is testing a new treatment that uses a patient's own modified immune cells to target and kill cancer cells. It focuses on patients whose ovarian, fallopian tube, or primary peritoneal cancer has come back or hasn't responded to other treatments.

Who is the study for?
This trial is for adults with recurrent ovarian, fallopian tube, or primary peritoneal cancer who've had at least one platinum-based and two other chemotherapy treatments. They must have a life expectancy of over 3 months, no recent anticancer therapy or immunotherapy, and agree to use contraception. The cancer must express FSHR antigen.
What is being tested?
The study tests the safety of genetically modified T cells targeting the FSH receptor in patients with certain types of ovarian cancers. It explores treatment effectiveness both with and without additional chemotherapy.
What are the potential side effects?
Potential side effects may include immune reactions due to genetic modification of T cells, typical chemotherapy-related issues like nausea and fatigue if used alongside chemo, as well as site-specific complications from port placement.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had 1 platinum-based and at least 2 other chemotherapy treatments for ovarian, peritoneal, or fallopian tube cancer.
Select...
I haven't had immunotherapy with checkpoint inhibitors in the last 6 months.
Select...
I agree to have a port placed in my abdomen for treatment.
Select...
I can take care of myself but cannot do any physical work.
Select...
My cancer can be measured or detected by tests.
Select...
My cancer tests positive for the FSHR antigen.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had issues like an abdominal fistula, gut perforation, or abscess.
Select...
I have had abdominal surgery not related to IP port placement.
Select...
I have signs of a blocked intestine or need IV fluids or feeding.
Select...
I might have untreated cancer spread to my brain.
Select...
I haven't had a heart attack or serious heart rhythm problems in the last 6 months.
Select...
I do not have severe heart disease or symptoms of heart failure.
Select...
I have a history of serious seizures.
Select...
I have had radiation therapy to my abdomen or pelvis.
Select...
I have an active hepatitis B, or a history of hepatitis C or HIV.
Select...
I have cancer spread to the brain or its coverings.
Select...
I have a severe heart condition with very low heart pump efficiency.
Select...
I am not currently receiving treatment for any other cancer besides the one being studied.
Select...
I do not have extensive abdominal adhesions that would prevent surgery.
Select...
I have an autoimmune disease, but it's not thyroid-related or my thyroid condition is stable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum Tolerated Dose of FSHCER T Cells
Secondary study objectives
Duration of Response
Duration of Stable Disease
Overall Survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

10Treatment groups
Experimental Treatment
Group I: Intravenous treatment - Dose Level 5Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^7 by Intravenous (IV).
Group II: Intravenous treatment - Dose Level 4Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^6 by Intravenous (IV).
Group III: Intravenous treatment - Dose Level 3Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^6 by Intravenous (IV).
Group IV: Intravenous treatment - Dose Level 2Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^5 by Intravenous (IV).
Group V: Intravenous treatment - Dose Level 1Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^5 by Intravenous (IV).
Group VI: Intraperitoneal treatment- Dose Level 5Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^7. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
Group VII: Intraperitoneal treatment- Dose Level 4Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
Group VIII: Intraperitoneal treatment- Dose Level 3Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
Group IX: Intraperitoneal treatment- Dose Level 2Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
Group X: Intraperitoneal treatment- Dose Level 1Experimental Treatment1 Intervention
Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ovarian cancer include platinum-based chemotherapy, PARP inhibitors, and investigational therapies like genetically modified T cells targeting FSHR. Platinum-based chemotherapy works by causing DNA damage that cancer cells cannot repair, leading to cell death. PARP inhibitors prevent cancer cells from repairing DNA damage, particularly effective in cancers with BRCA mutations or homologous recombination deficiencies. Genetically modified T cells, such as FSHCER T cells, are designed to target specific receptors on cancer cells, enhancing the immune system's ability to recognize and destroy these cells. These treatments are crucial as they offer targeted approaches to combat ovarian cancer, potentially improving survival rates and reducing recurrence.

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
559 Previous Clinical Trials
144,549 Total Patients Enrolled
10 Trials studying Ovarian Cancer
569 Patients Enrolled for Ovarian Cancer
Anixa Biosciences, Inc.UNKNOWN
1 Previous Clinical Trials
45 Total Patients Enrolled
Robert M Wenham, MD, MS, FACOG, FACSPrincipal InvestigatorMoffitt Cancer Center

Media Library

Follicle Stimulating Hormone Receptor T Cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05316129 — Phase 1
Ovarian Cancer Research Study Groups: Intravenous treatment - Dose Level 2, Intravenous treatment - Dose Level 3, Intraperitoneal treatment- Dose Level 4, Intravenous treatment - Dose Level 4, Intraperitoneal treatment- Dose Level 5, Intravenous treatment - Dose Level 5, Intraperitoneal treatment- Dose Level 3, Intraperitoneal treatment- Dose Level 1, Intravenous treatment - Dose Level 1, Intraperitoneal treatment- Dose Level 2
Ovarian Cancer Clinical Trial 2023: Follicle Stimulating Hormone Receptor T Cells Highlights & Side Effects. Trial Name: NCT05316129 — Phase 1
Follicle Stimulating Hormone Receptor T Cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05316129 — Phase 1
~6 spots leftby Mar 2025